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The Journal of Internal Medicine Symposium 'Multimorbidity research at the crossroads: developing the evidence for clinical practice and health policy' was held at the Nobel Forum in Stockholm on 21 May 2018. A workshop took place the subsequent day with 18 multidisciplinary experts from North America and Europe that had taken part in the Symposium and that represented a wide range of professional backgrounds, including clinical care (geriatrics, primary care and internal medicine), public health and epidemiology, and pharmacology and health services research. The topics discussed (summarized as lessons learned in Box 1) covered issues related to the epidemiology, clinical care and the evaluation of healthcare performance in patients with multiple chronic conditions.
The growing interest in multimorbidity derives from the urgent need to provide better care and treatment to the increasing numbers of people suffering from it. If there is one common denominator for the majority of adults, and particularly older adults, that are seen in different care settings across the globe, it is that they suffer from multiple coexisting diseases. In primary care, the prevalence of people with two or more chronic diseases increases from 20% before the age of 40 years to 75% at 70 years [1] . However, our knowledge on the pathophysiology and psychosocial processes underlying multimorbidity and the responses needed from clinical care and health policy are still tentative. Even if some individuals seem exceedingly prone to develop and accumulate chronic diseases faster than the general population [2] , the biological mechanisms underlying such diversity are largely unknown, which hampers the development of targeted preventive and therapeutic Box 1. JIM Symposium 'Multimorbidity research at the crossroads: developing the evidence for clinical practice and health policy': lessons learned
Epidemiology
• Frailty, multimorbidity and disability overlap substantially at an individual level but are distinct constructs: a high proportion of individuals meeting the criteria for one do not meet those for others. Definitions of each construct may need to be tailored to each specific purpose and context.
• A life course approach will help in understanding the complexity behind these three constructs by providing a framework that encompasses the physical and social environment, as well as the biological mechanisms.
• Research on patterns of multimorbidity and rate of disease accumulation has the potential to address common disease pathways and develop efficient preventive and curative interventions. Future research needs to establish the internal and external validity of such clusters, their social determinants, longitudinal patterns of association, gender differences and interactions with other geriatric syndromes.
Clinical care
• Models of care are still informed by single- interventions. The three reviews, which were prepared in relation to the Symposium and outlined below, aimed at facilitating progress by presenting the state of the art of current knowledge on concepts, underlying mechanisms, clinical management and performance measurement.
An integrated approach that also takes into account functional aspects (i.e. limitations in mobility, strength or cognition) is crucial to better understanding the development and consequences of multimorbidity [3] . Indeed, multimorbidity and function are bidirectionally associated [4] . On the one hand, diseases belonging to common patterns of multimorbidity may interact, curtailing compensatory mechanisms and resulting in physical and cognitive decline. On the other hand, physical and cognitive impairments affect the severity and burden of multimorbidity, contributing to the establishment of a vicious circle. Thus, instead of a simple linear pathway that leads from multimorbidity to functional impairment, a multimorbidityfunctional impairment synergistic and time-dependent circle is probably a better representation of the health and social care needs of older adults and may allow physicians to more easily weigh treatment benefits and risks.
Furthermore, shared lifelong risk factors seem to underlie multimorbidity, functional impairment and their interplay [3] . For example, older age, obesity, involuntary weight loss and sedentarism can accelerate damage accumulation in organs and physiological systems by fostering inflammatory status. Inappropriate use or overuse of specific medications and drug-drug and drug-disease interactions also contribute to the bidirectional association between multimorbidity and functional impairment. Additionally, psychosocial factors such as low socioeconomic status and the direct or indirect effects of negative life events, weak social networks and an external locus of control may nurture the complex interactions between multimorbidity, functional decline and negative outcomes.
Although the evidence supporting the integrative assessment of both multimorbidity and functional impairment in research and clinical practice is increasing, there are still important knowledge gaps. Deciphering the scenarios in which patients with multimorbidity should be assessed for physical and cognitive impairment is one priority research area. Gaining deeper knowledge of the link between the biology of ageing and the development of multimorbidity and functional impairment is another research area to be considered.
In clinical practice, the presence of multiple conditions makes patient management more difficult, outcomes less certain and often renders traditional disease-oriented clinical practice guidelines (CPGs) lacking, that is multiple conditions with multiple aetiological factors and multiple management options, and involving a wide range of health professionals.
• In the clinical management of people with multimorbidity, the presence of conflicting priorities means that trade-offs and personalized management are necessary, that is the use of outcomes that are meaningful to patients (e.g. function), the formulation of explicit priorities and goals, and appropriate interventions both in terms of time to and absolute benefit and burden.
• Continuity of care offers an instrument to potentially maximizing the effectiveness of multidisciplinary care teams whilst ensuring patient-centredness. Whilst care continuity is expected to improve satisfaction and outcomes, reduce costs and lead to more appropriate decisions, evidence is still scant.
Health policy
• Performance assessment frameworks for people with multimorbidity should focus not only on the use of therapies likely to benefit these patients, but also on those unlikely to benefit or even likely to harm them. They also need to capture patients' voices (both in the form of patient-reported experiences and outcomes -PREMs and PROMs-) and establish whether patient preferences and values inform decision-making.
• The design of healthcare systems for patients with complex needs will benefit from attention to the following key issues: patient selection and targeting, patient engagement, caregiver involvement, coordination of care, information systems, workforce planning, aligning funding and incentives, enabling innovation and learning from experience.
inadequate. Available supporting tools do not generally fit for purpose for patients with multimorbidity as they have been developed mostly within a single-disease framework. There are nonetheless specific CPGs that address a range of areas beyond the usual realms of disease-oriented guidelines, but they vary in the degree of specificity and detail.
General guidance (such as the Ariadne principles [5] ), as well as a some specific CPGs addressing multimorbidity (diagnosis oriented) and polypharmacy (treatment oriented), support decision-making in these patients. However, as scientific evidence is still scant, expert consensus is often the only available method underlying these guidelines. In line with this, few detailed and actionable clinical recommendations are available and there is a paucity of tools to support decision-making [6] . Most of the available CPGs emphasize the importance of communication with patients and their carers about the patient's needs, priorities and preferences for tailoring care to these heterogeneous groups, improving patient-centred health outcomes and minimizing the burden of care and overtreatment. Continuous structured communication and elicitation of patients' preferences are necessary as they may shift over time.
The limited availability of reliable risk prediction models and weak consensus on appropriate outcomes of care highlight major research deficits. Research is also needed on interventions that support individual goal and priority setting, strategies to reduce barriers to self-management, and reliable methods for the identification and care of those most at risk of adverse events. Finally, an integrated approach to both multimorbidity and polypharmacy should be considered in the development of future guidelines.
From a health policy perspective, the design of healthcare systems for patients with complex needs will benefit from a learning organization approach and an orientation to innovation that considers patient selection, targeting, and engagement, caregiver involvement and coordination of care, as well as the alignment of funding and incentives, workforce planning and information systems.
Specific models of care had to be developed when epidemiological transitions rendered models essentially oriented to an acute disease ineffective for chronic conditions [7] . Similarly, multimorbidity care models need to be developed that consider the integration of care across conditions and providers and patient-centred care with explicit goal setting and prioritization. Patient-focussed services, such as primary care and geriatric medicine, will play a key role in the design of such models [8, 9] . Current approaches to the measurement of performance do not capture the complexity of care required for people with multimorbidity. The assessment of performance should be aligned with these proposed new models of care [10] .
The association between quality of care and multimorbidity is complex [10] . It depends on the nature of conditions involved and the approach used for measuring quality. People with conditions that are not part of the same pathophysiological pathway may be disadvantaged by current approaches to performance assessment, particularly when they are linked to financial incentives. Performance assessment frameworks for people with multimorbidity should consider not only the use of therapies likely to benefit these patients, but also those unlikely to benefit or even likely to harm them. Such frameworks require valid indicators for quality of care processes and outcomes that capture performance of care as delivered across conditions and providers, as well as both the elicitation of patient preferences and values in the form of patient-reported experiences (PREMs) and outcomes of care (PROMs) and establishing whether patient preferences and values effectively inform decision-making.
The common thread across these three reviews is the need for a truly patient-centred care that takes into account the individual patient from a comprehensive and multidimensional perspective and acknowledges the complexity and dynamics of older adults' health. This requires a great investment in future research to develop new interdisciplinary methods and to promote integrative and innovative research avenues going from prevention and medical treatment to pathways of healthcare delivery.
